Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.50 |
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957673 | 0.84 | MCL1 (0.49) | MCL1ALDH1A1PKMSLC6A4HTR2A | |
| SCHEMBL6151984 | 0.84 | SLC6A4 (0.66) | SLC6A4HTR2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL22957856 | 0.83 | HDAC3 (0.49) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL16797883 | 0.82 | HDAC3 (0.46) | ALDH1A1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL13875905 | 0.82 | HTT (0.51) | PKMSLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL29808598 | 0.82 | GAA (0.54) | ALDH1A1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL13359870 | 0.82 | TAAR1 (0.53) | ALDH1A1SLC6A4HTR2ASLC6A2SLC6A3 | |
| SCHEMBL24710168 | 0.81 | MAPT (0.58) | ALDH1A1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL15979344 | 0.81 | TACR1 (0.45) | SLC6A4SLC6A2SLC6A3CYP2C19HDAC3 | |
| SCHEMBL18588991 | 0.81 | SLC6A4 (0.59) | MCL1ALDH1A1PKMSLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365567-A1 | COMPOUNDS | Esfam Biotech Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
| CN-116829558-A | Compounds of formula (I) | 艾斯法姆生物技术股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-4188933-A1 | COMPOUNDS | Esfam Biotech Pty Ltd. (AU) | 2023-06-07 | — | — | EP | disclosed |
| EP-3849968-B1 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | BRISTOL MYERS SQUIBB CO (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3177612-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2022-02-23 | — | — | EP | disclosed |
| US-11254681-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| WO-2022020887-A1 | TREATMENT OF CD151 RELATED DISORDERS | Esfam Biotech Pty Ltd (AU) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022020888-A1 | COMPOUNDS | Esfam Biotech Pty Ltd (AU) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022020890-A1 | TREATMENT OF VETERINARY CONDITIONS ASSOCIATED WITH CD151 | Esfam Biotech Pty Ltd (AU) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022020889-A1 | METHOD OF TREATMENT OF CYTOMEGALOVIRUS | Esfam Biotech Pty Ltd (AU) | 2022-02-03 | — | — | WO | disclosed |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | MORITA KOHEI (JP) | 2013-05-23 | — | — | US | disclosed |
| US-8334314-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-12-18 | — | — | US | disclosed |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| WO-2010139481-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010066847-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | CELLVIR (FR) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196453-A1 | Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents | Cellvir (FR) | 2010-06-16 | — | — | EP | disclosed |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| US-7247756-B2 | 1,4-disubstituted benzenes as insecticides | BAYER CROPSCIENCE AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-7247756-B2 | 1,4-disubstituted benzenes as insecticides | BAYER CROPSCIENCE AG (DE) | 2007-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254681-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | PPARD, PPARG, RORC | MCL1 1058/4885ALDH1A1 1245/4885PKM 1264/4885 |
| US-20230365567-A1 | COMPOUNDS | CD81, CD47, CD59 | MCL1 290/4885ALDH1A1 128/4885PKM 4516/4885 |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | MCL1 3798/4885ALDH1A1 3645/4885PKM 2447/4885 |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | MCL1 3041/4885ALDH1A1 839/4885PKM 2356/4885 |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | MCL1 3041/4885ALDH1A1 839/4885PKM 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.